Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06424444 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
A Phase 3 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 421
- Enrollment target
NCT06424444: Completed Phase 3 study, sponsored by Aldeyra Therapeutics.
NCT06424444 is a Phase 3 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 421 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06424444, a Phase 3 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 421 participants
- Enrollment target
Study Summary
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
Primary Outcome
Measured using a 0 - 100 visual analog scale where 0 is "no discomfort" and 100 is "maximal discomfort"
Interventions
- DRUG Vehicle ophthalmic solution
- DRUG Reproxalap ophthalmic solution (0.25%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2024-11-03 |
| Phase | Phase 3 |
What the finished NCT06424444 record still lists
NCT06424444 is an interventional study that assigns participants to a tested intervention. The registered 421 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle ophthalmic solution is the first listed.
NCT06424444 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06424444 about?
NCT06424444 is a clinical study titled "A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease". A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
What is the current status of trial NCT06424444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 421 participants. The study started on 2024-04-29. Estimated completion is 2024-11-03.
What interventions are being tested in trial NCT06424444?
The interventions under investigation include: Vehicle ophthalmic solution (DRUG), Reproxalap ophthalmic solution (0.25%) (DRUG).
Who is sponsoring clinical trial NCT06424444?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06424444's enrollment target sits among peer trials
421 890th of 2000 higher than 1,110 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05976763 · 421 participants · Phase 3
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- NCT07114601 · 421 participants · Phase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI